News for Crinetics Pharmaceuticals, Inc. (CRNX)

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company based in San Diego, announced on June 10, 2025, the granting of non-qualif

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company specializing in endocrine disease therapeutics, announced on May 23, 2025,

Crinetics Pharmaceuticals (CRNX) to present at Jefferies Global Healthcare Conference 2025. Presentation scheduled for June 5, 2025, at 12:50 p.m. Easte

**media[635255]**

Crinetics Pharmaceuticals, indicated by the ticker CRNX, has been awarded orphan drug designation by the FDA for its drug candidate, paltusotine. This designati

New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsGayathri Diwakar - Head-Investor...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Crinetics Pharmac

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NCRNX.OQ - Crinetics Pharmaceuticals IncQ1 2025 Crinetics Pharmaceuticals Inc Earnings CallMay

Crinetics Pharmaceuticals Inc's innovative pipeline offers potential in rare endocrine diseases and tumors.Financial analysis reveals a significant net loss, h

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company specializing in endocrine disease therapeutics, announced it will release

SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. ( CRNX) today announced that it will report first quarter 2025 financial results

**media[592536]**

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committe

Crinetics Pharmaceuticals (CRNX) grants stock options and RSUs to 26 new non-executive employees. Equity awards aim to attract new talent as per Nasdaq

**media[592063]**

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. ( CRNX) today announced that the European Medicines Agency (EMA) has validated t